Good prognosis for primary ovarian pure nongestational choriocarcinoma using the EMA/CO regime.
Nongestational choriocarcinoma of the ovary is a rare germ cell tumor with a worse prognosis than gestational choriocarcinoma. In this report we present a case of nongestational chroriocarcinoma where the EMA/CO regime was applied. The clinical features, management, and outcome are discussed.
Ozturk
E
E
Department of Obstetrics and Gynecology, Gaziantep University, Gaziantep, Turkey. ebruozturkarslan@yahoo.com
Ugur
M Gurol
MG
Cebesoy
F Bahar
FB
Aydin
A
A
Sever
T
T
Balat
O
O
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D031954:Choriocarcinoma, Non-gestational / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate